SGN-LIV1A Uses, Dosage, Side Effects and more
SGN-LIV1A is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
| Trade Name | SGN-LIV1A |
| Generic | Ladiratuzumab vedotin |
| Ladiratuzumab vedotin Other Names | Ladiratuzumab vedotin, SGN-LIV1A |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
